Dr. Schmidt reports grants and personal fees from UCB, grants and personal fees from Biotest, grants from Incyte, grants from Euroimmun, personal fees from Novartis, grants and personal fees from ArgenX, personal fees from Astra Zeneca, grants and personal fees from Fresenius Medical Care, grants from Dompe, grants from Synthon, grants from Admirx and personal fees from Thermo Fisher, outside the submitted work; Dr. Amagai reports grants from Ono Pharmaceutical Company, grants from MBL and grants from RegCell, outside the submitted work; Dr. Fairley reports grants from National Institutes of Health and other from AstraZeneca, outside the submitted work; Dr. Murrell has served as a Principal Investigator and Advisor for trials with Principia Biopharma, Roche and Sanofi; Dr. Payne reports grants, personal fees and non‐financial support from Cabaletta Bio and personal fees from Villaris Therapeutics, outside the submitted work; in addition, Dr. Payne has a patent Compositions and methods of chimeric autoantibody receptor T cells with royalties paid from Cabaletta Bio, a patent Compositions and methods for selective protein expression with royalties paid from Novartis, and a patent Method of redirecting T cells to treat HIV infection with royalties paid from Tmunity; Dr. Zillikens reports personal fees from UCB, Almirall, ArGEN‐x, grants from Biotest, Euroimmun, Fresenius, personal fees from Biotest, Fresenius, Miltenyi, Roche, Biogen, Abbvie, UCB, Janssen, Novartis, outside the submitted work; Mr. Yale and Drs. Kasperkiewicz, Joly and Woodley have nothing to disclose.